Hypergonadotropic Hypogonadism: Management of Infertility.
Hypergonadotropic hypogonadism
aromatase inhibitors
empirical medical treatment
gonadotropins
male infertility
selective
estrogen receptor modulators.
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
Historique:
received:
31
03
2020
accepted:
16
08
2020
pubmed:
4
11
2020
medline:
25
2
2023
entrez:
3
11
2020
Statut:
ppublish
Résumé
Medical treatments are used either alone or in combination with assisted reproductive techniques for the treatment of infertile patients with hypergonadotropic hypogonadism. A wide range of treatment options such as gonadotropins, aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and their combination are available as options. The aim of this review was to evaluate treatment options for infertile men with hypergonadotropic hypogonadism. A literature search of MEDLINE (1980-2019) was conducted using the terms 'hypogonadism', 'male infertility', 'gonadotropins', 'SERMs' and 'AIs'. Pathologies leading to hypergonadotropic hypogonadism and treatment modalities such as gonadotropins, SERMs, AIs and surgical treatment were discussed. FSH increases spontaneous pregnancy rates but the level of evidence was proven to be low for live birth rates. AIs are valid treatment options for patients with low T/E2 ratio as they significantly increase sperm concentrations. SERMs are recommended for infertile males with a sperm concentration between 10-20 million. Varicocele was reported to increase testosterone levels of hypogonadic infertile males. Medical treatment modalities such as gonadotropins, SERMs, AIs and a combination of these therapies has been showed to have some effect in improvement of fertility but is not mainstream of the treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Medical treatments are used either alone or in combination with assisted reproductive techniques for the treatment of infertile patients with hypergonadotropic hypogonadism. A wide range of treatment options such as gonadotropins, aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) and their combination are available as options.
OBJECTIVE
OBJECTIVE
The aim of this review was to evaluate treatment options for infertile men with hypergonadotropic hypogonadism.
METHODS
METHODS
A literature search of MEDLINE (1980-2019) was conducted using the terms 'hypogonadism', 'male infertility', 'gonadotropins', 'SERMs' and 'AIs'. Pathologies leading to hypergonadotropic hypogonadism and treatment modalities such as gonadotropins, SERMs, AIs and surgical treatment were discussed.
RESULTS
RESULTS
FSH increases spontaneous pregnancy rates but the level of evidence was proven to be low for live birth rates. AIs are valid treatment options for patients with low T/E2 ratio as they significantly increase sperm concentrations. SERMs are recommended for infertile males with a sperm concentration between 10-20 million. Varicocele was reported to increase testosterone levels of hypogonadic infertile males.
CONCLUSION
CONCLUSIONS
Medical treatment modalities such as gonadotropins, SERMs, AIs and a combination of these therapies has been showed to have some effect in improvement of fertility but is not mainstream of the treatment.
Identifiants
pubmed: 33138760
pii: CPD-EPUB-111074
doi: 10.2174/1381612826666201102110456
doi:
Substances chimiques
Aromatase Inhibitors
0
Selective Estrogen Receptor Modulators
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2790-2795Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.